These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16087398

  • 21. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis.
    Geller BL, Deere J, Tilley L, Iversen PL.
    J Antimicrob Chemother; 2005 Jun; 55(6):983-8. PubMed ID: 15872045
    [Abstract] [Full Text] [Related]

  • 22. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.
    Dirin M, Winkler J.
    Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc.
    Hudziak RM, Summerton J, Weller DD, Iversen PL.
    Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):163-76. PubMed ID: 10905553
    [Abstract] [Full Text] [Related]

  • 26. Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.
    Devi GR.
    Methods Mol Biol; 2009 Jun; 542():351-61. PubMed ID: 19565912
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.
    Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, Wilton SD, Buchmeier MJ, Lebleu B, Iversen PL.
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):826-8. PubMed ID: 17635157
    [Abstract] [Full Text] [Related]

  • 29. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.
    Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.
    Antimicrob Agents Chemother; 2009 May; 53(5):2089-99. PubMed ID: 19223614
    [Abstract] [Full Text] [Related]

  • 30. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P, Temsamani J.
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers.
    Geller BL, Deere JD, Stein DA, Kroeker AD, Moulton HM, Iversen PL.
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3233-9. PubMed ID: 14506035
    [Abstract] [Full Text] [Related]

  • 32. Novel targeting of cyclooxygenase-2 (COX-2) pre-mRNA using antisense morpholino oligonucleotides directed to the 3' acceptor and 5' donor splice sites of exon 4: suppression of COX-2 activity in human amnion-derived WISH and myometrial cells.
    Tyson-Capper AJ, Europe-Finner GN.
    Mol Pharmacol; 2006 Mar; 69(3):796-804. PubMed ID: 16354766
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo.
    Li YF, Morcos PA.
    Bioconjug Chem; 2008 Jul; 19(7):1464-70. PubMed ID: 18564870
    [Abstract] [Full Text] [Related]

  • 36. Intranasal antisense therapy: preclinical models with a clinical future?
    Bitko V, Barik S.
    Curr Opin Mol Ther; 2007 Apr; 9(2):119-25. PubMed ID: 17458164
    [Abstract] [Full Text] [Related]

  • 37. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism.
    Arora V, Cate ML, Ghosh C, Iversen PL.
    Drug Metab Dispos; 2002 Jul; 30(7):757-62. PubMed ID: 12065433
    [Abstract] [Full Text] [Related]

  • 38. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 39. The disposition (ADME) of antisense oligonucleotides.
    Dvorchik BH.
    Curr Opin Mol Ther; 2000 Jun; 2(3):253-7. PubMed ID: 11249618
    [Abstract] [Full Text] [Related]

  • 40. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
    Davis RL, Homer VM, George PM, Brennan SO.
    Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.